By Elias Schisgall

Shares of Eton Pharmaceuticals rose after the company acquired U.S. commercialization rights to a treatment for proliferating infantile hemangioma, a form of non-cancerous tumor found in newborns.

Shares were up 8.2% at $18.39 in Monday morning trading. The stock has gained 22% in the past year.

The pharmaceutical company said Monday it has acquired the rights to Hemangeol, an oral solution developed by Pierre Fabre Medicament. With the acquisition, Eton said, it has reached a long-held goal of 10 commercial products.

"As the only treatment for infantile hemangiomas that require systemic therapy, Hemangeol is a critical medication and a strong fit with Eton's orphan-focused commercial model," Eton Chief Executive Sean Brynjelsen said.

The acquisition will be financed with cash on hand and is expected to be accretive to 2026 earnings.

Eton will take over the U.S. commercialization of Hemangeol from Pierre Fabre on May 1.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

March 02, 2026 11:59 ET (16:59 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.